会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • COMPOSITION FOR MUCOSAL ADMINISTRATION CONTAINING AGENT FOR ENHANCING MUCOSAL ABSORPTION OF PEPTIDE DRUG, AND ADMINISTRATION METHOD THEREOF
    • 用于增强胶原蛋白吸收肽肽药物的包含药物的组合物的组合物及其施用方法
    • US20110165195A1
    • 2011-07-07
    • US12602576
    • 2008-06-27
    • Masuo KondohHiroshi UchidaTakeshi HanadaMasato Hoshino
    • Masuo KondohHiroshi UchidaTakeshi HanadaMasato Hoshino
    • C07K14/33A61K38/02A61K38/16
    • A61K38/29A61K9/0019A61K9/0043A61K9/0073A61K38/164A61K38/2214A61K38/25A61K47/42A61K2300/00
    • A mucosal absorption-enhancing agent is provided that enables oral, nasal or pulmonary administration of peptide drugs whose administration route has heretofore been limited to the injections due to their poor absorption from the mucosa. Specifically, the mucosal absorption of peptide drugs via intestinal, pulmonary or nasal route can be enhanced by allowing the peptide drugs with the C-terminal fragment (C-CPE) of an enterotoxin (CPE) produced by the bacterium Clostridium perfringens of the genus Clostridium, in particular with the C-CPE or its mutants resulting from the substitution and/or deletion of one or several amino acid residues of the C-CPE to act thereon. The composition for mucosal administration of the present invention significantly enhances absorption of peptide drugs, such as human parathyroid hormone hPTH(1-34), human ghrelin and human motilin, through the mucosa of small intestine, lung, nasal cavity and other mucosa. Also, unlike any of the conventional mucosal absorption-enhancers, the composition for mucosal administration of the present invention does not cause tissue damage and is therefore highly safe for use.
    • 提供了一种粘膜吸收增强剂,其能够口服,鼻或肺给予肽药物,其药物途径迄今为止由于其对粘膜的吸收差而限于注射。 具体地说,可以通过使具有由梭菌属产气荚膜梭菌(Clostridium perfringens)产生的肠毒素(CPE)的C末端片段(CPE)的C末端片段(CPE)的肽药物与肽药物的粘膜吸收, 特别是C-CPE或其由C-CPE的一个或几个氨基酸残基的取代和/或缺失产生的突变体作用于其上。 本发明的粘膜给药组合物通过小肠,肺,鼻腔和其他粘膜的粘膜显着增强肽药物如人甲状旁腺激素hPTH(1-34),人生长素释放肽和人胃动素的吸收。 此外,与任何常规的粘膜吸收增强剂不同,本发明的粘膜给药用组合物不会引起组织损伤,因此高度安全使用。
    • 5. 发明授权
    • Load current detecting device for pulse width modulation inverter
    • 脉宽调制逆变器负载电流检测装置
    • US4772996A
    • 1988-09-20
    • US36862
    • 1987-04-09
    • Hiroyuki HaneiTakeshi HanadaKenji KuboMasahiko WatanabeTsutomu OmaeToshihiko Matsuda
    • Hiroyuki HaneiTakeshi HanadaKenji KuboMasahiko WatanabeTsutomu OmaeToshihiko Matsuda
    • H02M7/5387H02M7/537
    • H02M7/53873
    • A PWM inverter includes a plurality of arms connected in parallel with a d.c. power source. Each arm is constituted by an upper arm and a lower arm each having a switching element. A plurality of switching control signals are continuously and alternately applied to one and the other of the two switching elements constituting the same arm respectively. In the PWM inverter, shunt resistors are connected between a minus terminal of the d.c. power source and the lower arms respectively. The PWM inverter further comprises a waveform command generating circuit generating commands representative of current waveforms to be supplied to a load, a carrier wave generating circuit and sample-hold circuits. Each of the sample-hold circuits samples and holds a terminal voltage of the associated shunt resistor in synchronism with the period of the carrier wave generated from the carrier wave generating circuit and at specific timing in a conduction period of the associated switching element.
    • PWM逆变器包括与直流电路并联连接的多个臂。 能量源。 每个臂由具有开关元件的上臂和下臂构成。 多个开关控制信号分别连续交替地施加到构成相同臂的两个开关元件中的一个和另一个。 在PWM逆变器中,分流电阻连接在直流负载端子之间。 电源和下臂。 PWM逆变器还包括产生表示要提供给负载的电流波形的指令的波形指令产生电路,载波发生电路和采样保持电路。 每个采样保持电路与从载波产生电路产生的载波的周期和相关的开关元件的导通周期中的特定定时同步地采样并保持相关联的分流电阻器的端子电压。
    • 7. 发明申请
    • Liquid Preparation of Physiologically Active Peptide
    • 液体制备生理活性肽
    • US20080193997A1
    • 2008-08-14
    • US11660406
    • 2005-08-24
    • Masaru MatsumotoMasako MatsumotoTakeshi HanadaNaomi Wakabayashi
    • Masaru MatsumotoMasako MatsumotoTakeshi HanadaNaomi Wakabayashi
    • C12N9/94
    • A61K9/0019A61K38/25A61K47/10A61K47/12A61K47/22A61K47/26A61K47/40
    • An effective liquid preparation achieves high bioavailability (BA) of physiologically active peptides or proteins, including ghrelins, that are administered as drugs. Also provided is a method for improving the BA of physiologically active peptides or proteins, including ghrelins, that are subcutaneously injected in aqueous solutions. The liquid preparation contains: a physiologically active peptide or protein, such as ghrelins, as an active ingredient; an acid solution including one or a combination of two or more selected form the group consisting of acetic acid, lactic acid, phosphoric acid, glycine, citric acid, hydrochloric acid, propionic acid, butyric acid, benzoic acid and salts thereof; an alcohol; and a polar organic liquid including one or a combination of two or more selected from the group consisting of N-methyl-2-pyrrolidone, dimethylformamide, dimethylsulfoxide and methylparaben.
    • 有效的液体制剂实现了作为药物施用的生理活性肽或蛋白质(包括生长素释放肽)的高生物利用度(BA)。 还提供了一种用于改善皮下注射在水溶液中的生理活性肽或蛋白质(包括生长素释放肽)的BA的方法。 液体制剂含有:生理活性肽或蛋白质,如生长素释放肽,作为活性成分; 包括选自乙酸,乳酸,磷酸,甘氨酸,柠檬酸,盐酸,丙酸,丁酸,苯甲酸及其盐中的一种或两种以上组合的酸溶液; 酒精; 以及包含选自N-甲基-2-吡咯烷酮,二甲基甲酰胺,二甲基亚砜和对羟基苯甲酸甲酯中的一种或两种以上的组合的极性有机液体。